Schizophrenia Clinical Trials

A listing of 89 Schizophrenia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Schizophrenia

85 - 89 of 89

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 89 active clinical trials seeking participants for Schizophrenia research studies. The states with the highest number of trials for Schizophrenia participants are California, Florida, Texas and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Adapting the Tumor Board Model for Mental Illness and Cancer

NCT05837598

Recruiting

This study examines the feasibility and acceptability of a virtual tumor board for cancer and mental illness for patients with serious mental illness and a new cancer diagnosis. The study also examines the impact on patient care, psychiatric symptoms, and clinician self-efficacy in managing this population.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/01/2023

Locations: Mass General/North Shore Center for Outpatient Care, Danvers, Massachusetts

Conditions: Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Genitourinary Cancer

Learn More ›

Siltuximab in Schizophrenia

NCT02796859

Recruiting

This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Siltuximab (Sylvant) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia. Siltuximab (structural formula C6450H9932N1688O2016S50) is a recombinant chimeric (human-murine) anti-human interleukin-6 (IL-6) monoclonal antibody. Siltuximab is formulated as a concentrate for solution for infusion, and will be administered by intravenous infusion. The investigators propose a 9-week randomized controlled trial of siltuximab, given in adjunct to antipsychotics, in N=30 stable outpatients with schizophrenia or schizoaffective disorder and evidence of increased inflammation in the peripheral blood (high-sensitivity C-reactive protein \[hsCRP\] \>0.5 mg/dL). The investigators hypothesize that adjunctive treatment with siltuximab will be associated with significant improvement in cognition compared to placebo in patients with schizophrenia, baseline IL-6 levels are higher in siltuximab-treated responders versus non-responders, and there will be greater decreases in hsCRP from baseline to week 6 in siltuximab-treated versus placebo-treated responders, with response defined as ≥0.5 SD improvement in cognition. Siltuximab is administered as an intravenous infusion every 3 weeks. Following a screening evaluation, participants will receive three infusions of siltuximab, one at baseline, another at week 3 of the study, and another at week 6. The investigators will measure changes in cognitive function and symptoms over a 9-week period. Complementing previous positive clinical trials of non-steroidal anti-inflammatory drugs, this would be a "proof-of-concept" study that targeting specific cytokines is a viable treatment for schizophrenia. Interleukin 6 and its receptor were discovered and cloned at Osaka University, Japan, by Tadamitsu Kishimoto in the 1980s. Janssen Pharmaceuticals, Inc. began the clinical development of siltuximab for the treatment of multicentric Castleman's disease, a rare blood disorder. Other clinical studies with siltuximab have been conduced for patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, and ovarian cancer. In April 2014,siltuxiumab was approved by the U.S. Food and Drug Administration (US FDA) as Sylvant for human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative multicentric Castleman's disease. Read Less

Gender:

ALL

Ages:

Between 18 years and 55 years

Trial Updated:

07/20/2023

Locations: Augusta University, Augusta, Georgia

Conditions: Schizophrenia, Psychotic Disorders

Learn More ›

Tocilizumab in Schizophrenia

NCT02874573

Recruiting

This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Tocilizumab (Actemra) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia. Tocilizumab (structural formula C6428H9976N1720O2018S42) is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin G1 (IgG1) subclass. Tocilizumab is formulated as a concentrate for solution for infusion, and will be administered by intravenous infusion. The investigators propose a 12-week randomized controlled trial of tocilizumab, given in adjunct to antipsychotics, in N=20 stable outpatients with schizophrenia or schizoaffective disorder and evidence of increased inflammation in the peripheral blood (high-sensitivity C-reactive protein \[hsCRP\]\>0.5 mg/dL). The investigators hypothesize that adjunctive treatment with tocilizumab will be associated with significant improvement in cognition compared to placebo in patients with schizophrenia, and baseline IL-6 levels are higher in tocilizumab-treated responders versus non-responders, and there will be greater decreases in hsCRP from baseline to week 12 in tocilizumab-versus placebo-treated responders, with response defined as ≥0.5 standard deviation (SD) improvement in cognition. Tocilizumab is administered as an intravenous infusion every 4 weeks. Following a screening evaluation, participants will receive three infusions of siltuximab, one at baseline, another at week 4 of the study, and another at week 8. The investigators will measure changes in cognitive function and symptoms over a 12-week period. Complementing previous positive clinical trials of non-steroidal anti-inflammatory drugs, this would be a "proof-of-concept" study that targeting specific cytokines is a viable treatment for schizophrenia. Interleukin 6 and its receptor were discovered and cloned at Osaka University, Japan, by Tadamitsu Kishimoto in the 1980s. In 1997, Chugai Pharmaceuticals began the clinical development of tocilizumab for the treatment of rheumatoid arthritis. Clinical studies for Castleman's disease and systemic juvenile idiopathic arthritis started in 2001 and 2002, respectively. Hoffmann-La Roche co-developed the drug due to a license agreement in 2003. On 11 January 2010, Tocilizumab was approved by the U.S. Food and Drug Administration (US FDA) as Actemra for the treatment of rheumatoid arthritis. The FDA approved tocilizumab for the treatment of systemic juvenile idiopathic arthritis for children from two years of age in April 2011. Read Less

Gender:

ALL

Ages:

Between 18 years and 55 years

Trial Updated:

07/20/2023

Locations: Augusta University, Augusta, Georgia

Conditions: Schizophrenia, Psychotic Disorders

Learn More ›

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia

NCT04519099

Recruiting

To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d

Gender:

All

Ages:

Between 18 years and 64 years

Trial Updated:

08/17/2020

Locations: Pillar Clinical Research, Bentonville, Arkansas +120 locations

Pillar Clinical Research, Bentonville, Arkansas

Woodland International Research Group, Little Rock, Arkansas

Woodland Research Northwest, LLC, Rogers, Arkansas

California Pharmaceutical Research Institute, Inc., Anaheim, California

Advanced Research Center, Inc., Anaheim, California

CITrials - Bellflower, Bellflower, California

Synexus California, Cerritos, California

ATP Clinical Research, Inc., Costa Mesa, California

ProScience Research Group, Culver City, California

Collaborative Neuroscience Network, LLC., Garden Grove, California

Behavioral Research Specialists, LLC, Glendale, California

Omega Clinical Trials, La Habra, California

Alliance Research, Long Beach, California

Synergy San Diego, National City, California

Excell Research, Inc, Oceanside, California

Orange County Neuropsychiatric Research Center, LLC d/b/a NRC Research Institute, Orange, California

CNRI Los Angelas, Pico Rivera, California

University of California San Diego/UCSD, San Diego, California

Artemis Institute for Clinical Research, San Diego, California

Schuster Medical Research Institute, Sherman Oaks, California

Collaborative Neuroscience Network, Torrance, California

University of Connecticut Health Center, Farmington, Connecticut

Wilks & Safirstein MD PA D/B/A MD Clinical, Hallandale Beach, Florida

Southern Winds Hospital, Hialeah, Florida

Research Centers of America, LLC, Hollywood, Florida

Meridien Research, Inc., Orlando, Florida

Synexus Atlanta, Atlanta, Georgia

Atlanta Center for Medical Research, Atlanta, Georgia

Agile Clinical Research Trials, LLC, Decatur, Georgia

iResearch Atlanta, Decatur, Georgia

Atlanta Behavioral Research, LLC, Dunwoody, Georgia

Inova Clinical Trials and Research Center, Tyrone, Georgia

Alexian Brothers Hospital Network, Hoffman Estates, Illinois

AMITA Health Alexian Brothers Center for Psychiatric Research, Hoffman Estates, Illinois

Louisiana Clinical Research, Shreveport, Louisiana

CBH Health LLC, Gaithersburg, Maryland

St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles, Missouri

Altea Research, Las Vegas, Nevada

Altea Research Institute, Las Vegas, Nevada

Hassman Research Institute, Berlin, New Jersey

Neurobehavioral Research Inc, Cedarhurst, New York

New Hope Clinical Research, Charlotte, North Carolina

Clinical Inquest Center Ltd, Beavercreek, Ohio

OSU Psychiatry Department, Columbus, Ohio

Professional Psychiatric Services, Mason, Ohio

Sooner Clinical Research, Oklahoma City, Oklahoma

Community Clinical Research, Inc., Austin, Texas

InSite Clinical Research, DeSoto, Texas

JOST Clinical Research, Houston, Texas

Pillar Clinical Research, Richardson, Texas

Mental Health Centre - Prof.Dr.Ivan Temkov-Burgas, Burgas, Not set

MHAT "Dr. Hristo Stambolski", EOOD, Kazanlak, Not set

State Psyciiatric Hospital - Lovech, Lovech, Not set

UMHAT Dr. Georgi Stranski, EAD, Pleven, Not set

Regional Psychiatric Dispensary Ruse, Ruse, Not set

MHAT-Targovishte, AD, Targovishte, Not set

DCC Mladost M - Varna, OOD, Varna, Not set

Inje University Busan Paik Hospital, Busan, Not set

Inje University Heaundae Paik Hospital, Busan, Not set

Chonnam National University Hospital, Gwangju, Not set

Gachon University Gil Medical Center, Incheon, Not set

Jeju National University Hospital, Jeju, Not set

University Kuala Lumpur, Ipoh, Not set

Sultanah Aminah Hospital, Johor Bahru, Not set

University Malaya Medical Center, Kuala Lumpur, Not set

Hospital Sentosa, Kuching, Not set

Szpital Uniwersytecki Nr.1 im. Dr. A. Jurasza, Klinika Psychiatrii, Bydgoszcz, Not set

Samodzielny Publiczny Zespół Opieki Zdrowotnej, Chełmno, Not set

Centrum Badan Klinicznych PI-House, Gdansk, Not set

Specjalistyczna Praktyka lekarska, Lublin, Not set

Indywidualna Praktyka Lekarska, Poznan, Not set

Mazowiecki Szpital Bródnowski w Warszawie Sp. z o. o. Bródnowskie Centrum Specjalistyczne, Warszawa, Not set

INSPIRA Clinical Research, San Juan, Not set

Spitalul de Psihiatrie si Neurologie Brasov, Brasov, Not set

Armys Clinical Emergency Central Hospital Prof Dr Carol Davila, Bucharest, Not set

Spitalul de Psihiatrie TITAN "Dr. Constantin Gorgoș", Bulevardul Nicolae Grigorescu, Nr. 41, București, Not set

CETTT SF Stelian Hospital, București, Not set

Spital Clinic Judetean Tg. Mures, Targu Mures, Not set

Sverdlovsk Regional Clinical Psychiatric Hospital, Ekaterinburg, Not set

Mental Health Research Centre, Dept. of Endogenous Psychic Disorders and Affective State, Moscow, Not set

Research Center of Mental Health, Moscow, Not set

Moscow Research Institute of Psychaitry - the Branch of V.Serbsky National Medical Research Centre of Psychiatry and Narcology), Moscow, Not set

State Healthcare Institution of Nizhegorodsky Region (SHI NR) 'Clinical Psychiatry Hospital #1 of Nizhny Novgorod City', Nizhny Novgorod, Not set

Kazan State Medical University, Respublika Tatarstan, Not set

Saratov City Clinical Hospital #2 n.a. V.I. Razumovsky, Saratov, Not set

Federal Budgetary State Institution National Medical Research Centre for Psychiatry and Neurology named after Bekhterev, St. Petersburg, Not set

National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev, St. Petersburg, Not set

City Psyconeurological Hospital #3 n.a. I.I. Skvortsov-Stepanov, St. Petersburg, Not set

Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Not set

Region Specialized Psychiatric Hospital #2, Tonnelniy, Not set

State Budget Healthcare Institution of Sverdlovsk Region "Sverdlovsk Regional Clinical Psychiatric Hospital", Yekaterinburg, Not set

Clinic of Psychiatric Diseases - Dr. Laza Lazarevic, Belgrade, Not set

Clinical Center of Serbia, Belgrade, Not set

Clinical Hospital Center Dr. Dragisa Misovic-Dedinje, Belgrade, Not set

Institute of Mental Health, Belgrade, Not set

Special Hospital for Psychiatric Diseases "Kovin", Kovin, Not set

Clinical Centre Kragujevac, Kragujevac, Not set

Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi, Novi Knezevac, Not set

Clinic for Psychiatry, Clinical Centre of Vojvodina, Novi Sad, Not set

Tri-Service General Hospital, Neihu, Not set

Taipei Tzu Chi Hospital, New Taipei City, Not set

National Cheng Kung University Hospital, Tainan City, Not set

Department of Psychiatry, Taipei Veterans General Hospital, Taiwan, Taipei City, Not set

Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Chiang Mai, Not set

Suanprung Psychiatric Hospital, Muang, Not set

Regional Psychonevrological Hospital #3, Frankivsk, Not set

Municipal Institution "Kharkiv Regional Clinical Psychiatric Hospital #3", Kharkiv, Not set

SI Institute of Neurology, Psychiatry and Narcology of NAMSU, Kharkiv, Not set

State Institution "Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine", Kharkiv, Not set

Kyiv Railway Clinical Hospital #2 of Branch "Health Center" of the Public Joint Stock Company "Ukrainian Railway"v, Kyiv, Not set

Kyiv Medical Regional Incorporation "Psychiatry". Center of Novel Treatment and Rehabilitation of Psychotic disorders, Kyiv, Not set

Geikivka Regional Psychiatric Hospital, Kyiv, Not set

Communal Institution of Lviv Regional Council Lviv Regional Clinical Psychiatric Hospital, Department #20, Lviv National Medical University named after Danylo Halytsky, Lviv, Not set

Odesa Regional Medical Center for Psychological Health of the Odesa Regional Council, Odesa, Not set

Odesa Regional Psychiatric Hospital No.2, Odesa, Not set

CI Kherson Regional Psychiatric Hospital of Kherson RC, Petrivka, Not set

CI Cherkasy Regional Psychiatric Hospital of ChRC, Smila, Not set

CI O.I. Yuschenko VRPsH Depts No.14 and No.15 M.I. Pyrogov VNMU, Vinnytsia, Not set

Vinnytsia Regional Psycho-Neurological Hospital, Vinnytsia, Not set

Conditions: Schizophrenia

Learn More ›

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

NCT03495024

Recruiting

To test the feasibility of studying effects of smoking cessation with varenicline on antipsychotic drug-induced neurological side effects, we propose a 12 week pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics. Subjects will be followed after a 2 week baseline period to assess changes in smoking status and neurological symptoms using... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

03/20/2019

Locations: Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania

Conditions: Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism

Learn More ›

85 - 89 of 89